Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2010  |  Volume : 6  |  Issue : 4  |  Page : 575-577

Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease

1 Kidney Cancer Research Bureau, Bazovskaya ul. 4/1 office 15, Moscow, Russia
2 N.N. Blokhin Russian Cancer Research Center, Dept.of Biotherapy, Moscow, Russia

Correspondence Address:
Ilya Tsimafeyeu
Bazovskaya ul. 4/1 office 15, Moscow
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-1482.77084

Rights and Permissions

We report on a family with von Hippel-Lindau (VHL) disease and atypically aggressive renal cell carcinoma. A woman and her brother had progressive VHL disease with multiple tumors in their kidneys. One patient developed pulmonary metastases. The patient who had localized disease received radiofrequency ablation with complete destruction of tumors. Cytoreductive nephrectomy was performed in the case of metastatic disease, following which sunitinib maleate (50 mg orally daily, 4 weeks on, 2 weeks off) was given. Examination after two treatment cycles showed complete regression of all metastases. For 19 months, the patients have been under active observation without disease progression. Also, we detected high immunohistochemical expression of vascular endothelial growth factor receptors 1 and 2 in the cytoplasm and nuclei of tumor cells.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded350    
    Comments [Add]    

Recommend this journal